[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561799":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":10,"centralContacts":21,"locations":27,"responsibleParty":42,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":10,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Karolinska Institutet","OTHER",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"Individuals with autoantibodies against Ro\u002FSSA and\u002For La\u002FSSB",null,[12],"Other: No intervention",{"label":14,"type":10,"description":10,"interventionNames":15},"Individuals without autoantibodies against Ro\u002FSSA and\u002For La\u002FSSB",[12],[17],{"type":6,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"No intervention","No intervention.",[9,14],[22],{"name":23,"role":24,"phone":25,"phoneExt":10,"email":26},"Albin Björk, MD, PhD","CONTACT","+46 8-123 687 04","albin.bjork@ki.se",[28],{"facility":29,"status":30,"city":31,"state":10,"zip":10,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Centrum för reumatologi","RECRUITING","Stockholm","Sweden","SE",{"type":35,"coordinates":36},"Point",[37,38],18.06871,59.32938,{"lat":38,"lon":37},[41],{"name":23,"role":24,"phone":25,"phoneExt":10,"email":26},{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Albin Björk","Principal Investigator","100561799","follow-up-study-of-individuals-with-autoantibodies-against-rossa-and-lassb-100561799",false,"NCT06594861","Follow-up Study of Individuals with Autoantibodies Against Ro\u002FSSA and La\u002FSSB","Follow-up of Clinical Manifestations and Inflammation-related Parameters in Individuals with Autoantibodies Against Ro\u002FSSA and La\u002FSSB","ProgreSS","Inclusion Criteria:\n\nTo be included in the risk group, the following criteria must be met:\n\n\\- At least one instance of testing positive for Ro\u002FSSA or La\u002FSSB, regardless of the method used.\n\nTo be included in the control group, the individual must:\n\n\\- Have no rheumatologic disease and no autoantibodies against Ro\u002FSSA or La\u002FSSB.\n\nExclusion Criteria:\n\n1. Below 18 years of age\n2. Inability to consent to their own participation\n3. Ongoing infection or severe illness where the study physician deems participation in the study not to be in the individuals best interest\n4. Inability to read and understand Swedish, and therefore unable to complete the forms and questionnaires included in the project",true,"ALL","18 Years",{"count":58,"type":59},500,"ESTIMATED","OBSERVATIONAL","In this study, individuals with autoantibodies against Ro\u002FSSA and La\u002FSSB will be followed with regard to clinical manifestations and immunological parameters to identify immunological changes, environmental factors, and early clinical symptoms that characterize the progression from serological autoreactivity to clinically manifest disease.",[63],"Autoantibodies","2024-09-10",{"date":66,"type":67},"2024-09-19","ACTUAL",{"date":69,"type":67},"2024-02-09",{"date":71,"type":59},"2038-12",{"name":5,"class":6},1]